Akeem Gardner is the Founder and CEO of Canurta. In 2018 Akeem acquired an Industrial Hemp License from Health Canada and began to farm hemp as he embarked on his entrepreneurial venture, which allowed him to meet with the University of Guelph professors in the summer of 2019 to begin the cannflavin project. 



At CannMed 23, he will present “Targeting Glioblastoma Invasion and Survival with Cannabis-Derived Flavonoids”. During our conversation, Akeem provides a preview of that presentation, and insights into the following topics: 



What are flavonoids and how are they different from cannabinoids and terpenes The flavonoids that are unique to cannabis, also known as cannflavins Why cannflavins are not as well-studies as other cannabis compoundsHow Akeem became interested in cannflavinsCantura’s method for isolating, capturing, and concentrating these moleculesPotential medical applications for cannflavins and how they may work in combination with cannabinoids



Thanks to This Episode’s Sponsor: Canurta



Canurta is a preclinical biotechnology company pioneering the discovery and production of novel, polyphenol-rich ingredients to improve chronic disease prevention and recovery. Their research and technology unlocks the significant anti-inflammatory, anti-viral, anti-cancer and neuroprotective potential of plant polyphenols. Canurta aspires to improve health outcomes, promote longevity and pull humans and animals out of the cycle of chronic disease.



To learn more visit canurta.com



Additional Resources



Interference of neuronal TrkB signaling by the cannabis-derived flavonoids cannflavins A and BAkeem Gardner on LinkedInRequest an Invitation to CannMed 23Review the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]Healthcare Provider Medical Cannabis Research Study